Infectious Disease · Clinical trials
Respiratory Syncytial Virus (RSV) Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About respiratory syncytial virus (rsv) — and why its trials are hard
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease (LRTD), causing bronchiolitis and pneumonia in infants and severe respiratory illness in older adults and those with cardiopulmonary conditions. After decades without active vaccines, 2023 was transformative: the FDA approved Arexvy (GSK) and Abrysvo (Pfizer), adjuvanted/bivalent prefusion F protein vaccines for adults 60 and older, and Abrysvo additionally for maternal immunization to protect newborns. Also in 2023, nirsevimab (Beyfortus), a long-acting monoclonal antibody, was approved for passive immunization of infants across an RSV season, complementing the older, more narrowly indicated palivizumab (Synagis). The primary efficacy endpoint across programs is prevention of RSV-associated LRTD. This progress followed a cautionary history: a 1960s formalin-inactivated RSV vaccine caused enhanced respiratory disease, and stabilization of the prefusion F antigen was the key scientific advance enabling modern vaccines. Safety monitoring continues, including attention to potential rare neuroinflammatory events and, for maternal vaccination, preterm birth signals.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| RSVPreF3 adjuvanted vaccine (Arexvy) | 2023 | Prefusion F protein vaccine (adjuvanted) for adults aged 60+ (later expanded to 50-59 at increased risk) | AReSVi-006 (phase 3, NEJM 2023) | Vaccine efficacy against RSV-associated lower respiratory tract disease | ~82.6% efficacy against RSV-LRTD over the first season in adults 60+. |
| Bivalent RSVpreF vaccine (Abrysvo) | 2023 | Bivalent prefusion F vaccine for adults 60+ and for maternal immunization (given in pregnancy to protect infants) | RENOIR (older adults) and MATISSE (maternal), phase 3, NEJM 2023/2024 | Efficacy against RSV-LRTD (older adults); infant medically attended severe RSV-LRTI (maternal) | Older adults ~66.7% against RSV-LRTD (>=2 signs); maternal ~81.8% against infant severe medically attended LRTI within 90 days of birth (~69% through 180 days). |
| Nirsevimab (Beyfortus) | 2023 | Long-acting anti-RSV F monoclonal antibody for passive immunization of infants for their first RSV season | MELODY (phase 3, NEJM 2022/2023) | Incidence of medically attended RSV-associated LRTI | ~74.5% (MELODY) reduction in medically attended RSV LRTI through 150 days after dosing. |
| Palivizumab (Synagis) | 1998 | Monthly monoclonal antibody prophylaxis for high-risk infants (prematurity, chronic lung/heart disease) | IMpact-RSV (phase 3, Pediatrics 1998) | RSV-related hospitalization | ~55% relative reduction in RSV hospitalization in high-risk infants versus placebo. |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in respiratory syncytial virus (rsv) development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Formalin-inactivated RSV vaccine (historic) — 1960s pediatric field trials | Not only failed to protect but caused vaccine-enhanced respiratory disease, with severe illness and infant deaths on natural RSV exposure | Non-protective/poorly neutralizing antibody and Th2-skewed immunopathology; delayed RSV vaccine development for decades. |
| Suptavumab (anti-RSV F mAb) — NURSERY (phase 3, Regeneron) | Failed to significantly reduce medically attended RSV LRTI in infants; program halted | A naturally circulating RSV-B mutation escaped the antibody's epitope, undermining efficacy. |
Choosing the right endpoint
Primary endpoints that matter in respiratory syncytial virus (rsv) trials
- RSV-associated lower respiratory tract disease (RSV-LRTD) — Primary efficacy endpoint for adult vaccines, typically defined by symptom criteria plus lab confirmation.
- Medically attended RSV LRTI — Primary endpoint for infant monoclonal antibodies (nirsevimab); captures real-world care-seeking illness.
- RSV-related hospitalization — Key severe-outcome endpoint, historically used for palivizumab in high-risk infants.
- Infant severe medically attended LRTI (maternal vaccine) — Endpoint for maternal immunization, measuring protection transferred to the newborn.
How iNGENū runs respiratory syncytial virus (rsv) trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Respiratory Syncytial Virus (RSV) clinical trials — FAQs
Who should get an RSV vaccine?
How are infants protected?
Why did RSV vaccines take so long?
Ready to discuss your respiratory syncytial virus (rsv) trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal